Primer: Shanghai HeartCare Medical Technology (6609 HK) - Aug 2026
Shanghai HeartCare is a rapidly growing domestic leader in China's neuro-interventional medical device market, poised to benefit from...
100 Views
Zylox-Tonbridge Medical Technology (2190.HK) - A Good Alpha-Generating Opportunity for Investors
​Zylox's strong fundamentals and growth potential have not been fully reflected in current valuation due to market conditions, making it a...
596 Views
Pre-IPO Zylox-Tonbridge Medical Technology - Promising Market with Challenges
This insights analyzed Zylox-Tonbridge Medical Technology in terms of the market potential, industry characteristics, business analysis, financial...
627 Views
China Healthcare Weekly Wrap (20-24 July)
SMMT 2Q26 on Akeso-partnered ivonescimab; positive profit alerts from Harbour, MicroPort MedBot, Shanghai HeartCare; Wuxi Bio hit 10,000 molecules;...
138 Views
APAC Healthcare Weekly (January 25) – InSilico, Daiichi, Shionogi, Alteogen, HK Inno, Sun Pharma
InSilico entered outlicensing deal. Daiichi’s Enhertu got China approval for 6th indication. Shionogi will pick up Pfizer’s stake in ViiV...
529 Views